A first-in-class humanized monoclonal antibody targeting CD38 for the treatment of multiple myeloma (MM) and autoimmune diseases. With FDA IND approval secured, this program addresses an $8B market opportunity with strong global patent protection.
Targets both the TH2 and TH1 pathways, the primary drivers of AD pathology. This differentiated dual-inhibitor approach is designed to deliver broader and more durable therapeutic response than single-pathway agents.
Novel mechanism targeting innate immune signaling at its molecular origin. A New Chemical Entity and the world's first small-molecule MyD88 inhibitor; set to enter clinical-stage compassionate use. Breakthrough results across multiple dermatological indications.
No competitor has reached clinical use with a small-molecule MyD88 inhibitor.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.